The clinical efficacy of CardioGraft-MC® patches is supported by a growing number of peer-reviewed clinical publications and industry event educational seminars. In addition to the clinical efficacy of a graft, cost considerations are equally important when deciding on a graft to use for your case as costs do not stop at the index procedure. Reoperations carry a risk of financial burden for patients and facilities, which are often not fully reimbursed for procedures.
An in-depth cost-effectiveness analysis was completed to highlight the cost-effectivness of the CardioGraft-MC cardiac patch versus alternative graft solutions.
One: 100 patients with cryopreserved or synthetic pulmonary arterioplasty patches. Reoperation rate with 16 months: 20% for cryopreserved patch failures; 4.9% for synthetic patch failures.
Two: 108 patients with decellularized CardioGraft MC pulmonary artery patches. No reoperations for patch related failures within 28 months.
The hospital cost of reoperations ranged from $50,221 to $133,209.
Precise facility charge data was available for 7 reoperations, which fall under 4 NS-DRG reimburement codes, reoperation resulted in a facility loss (difference between the actual cost to the facility and commercial payment) of $28,120, $58,864, and $88,948.
CardioGraft-MC pulmonary patch is a cost-effective alternative to cryopreserved and synthetic patches. Based on clinical data, faciilities and most importantly, patients, can avoid the risk of reoperation due to graft failure if CardioGraft-MC patch is used.